日前,业内传得沸沸扬扬的Shire公司收购Baxaita一案终于尘埃落定,Shire宣布这桩交易最终以320亿美元成交。据悉,Shire以现金18美元/股加上股权,共计每股45.57美元的收购价将Baxalta纳入麾下。这次收购让Shire瞬间完成了产业扩充,其业务从血液学拓展到免疫学、神经科学、溶酶体贮积症以及其他疾病领域。以罕见病为主要管线的Shire,合并后在拓展产 A few days ago, Shire’s acquisition of Baxaita was reported to have settled. Shire announced that the transaction was eventually completed at US$32 billion. It is learnt that Shire will include Baxalta under the purchase price of $45.57 per share for cash of $18 per share plus equity. The acquisition allowed Shire to complete an industrial expansion in an instant and expand its business from hematology to immunology, neuroscience, lysosomal storage disease and other diseases. Shire, which uses rare diseases as its main pipeline, expands after the merger